Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is planning to release its financial results for Q3 2023. The company announced it will release the earnings report for the period ended Sept. 30, 2023, on Nov. 14, 2023, before the market opens. In addition, the company also announced plans to host a corporate update conference call and live-audio webcast that same day; the call is slated to begin at 8:30 a.m. ET. Those interested in accessing the call can dial 877-407-3982 (toll free) or 201-493-6780 (international), then use the conference ID 13741390. A replay of the webcast will also be available on the Predictive Oncology website following the event.

To view the webcast, visit https://ibn.fm/XCHiS

To view the full press release, visit https://ibn.fm/zx9oc

About Predictive Oncology Inc.

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. With the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based, drug-discovery solutions, further complemented by its wholly owned CLIA lab and GMP facilities. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN